T1 Mapping in Heart Failure

Insights from T1 mapping in heart failure

Methods Sixteen healthy subjects and 35 patients with heart failure awaiting guideline indicated CRT or primary prevention ICD (16 non ischemic cardiomyopathy (NICM), 19 ischemic cardiomyopathy (ICM)) were scanned on a 1.5T Magnetom Avanto (Siemens Healthcare, Erlangen) using a MOLLI (investigational WIP#448, 5:3:3 acquisition scheme, motion correction and automatically generated T1 map). In al...

T1 mapping in ischaemic heart disease.

A unique feature of cardiac magnetic resonance is its ability to characterize myocardium. Proton relaxation times, T1, T2, and T2* are a reflection of the composition of individual tissues, and change in the presence of disease. Research into T1 mapping has largely been focused in the study of cardiomyopathies, but T1 mapping also shows huge potential in the study of ischaemic heart disease. In...

T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure

Heart failure (HF) is a major and growing cause of morbidity and mortality. Despite initial successes, there have been few recent therapeutic advances. A better understanding of HF pathophysiology is needed with renewed focus on the myocardium itself. A new imaging technique is now available that holds promise. T1 mapping is a cardiovascular magnetic resonance (CMR) technique for non-invasive m...

T1 mapping in heart failure: from technique to prognosis, toward altering outcome.

T1-mapping in the heart: accuracy and precision

The longitudinal relaxation time constant (T1) of the myocardium is altered in various disease states due to increased water content or other changes to the local molecular environment. Changes in both native T1 and T1 following administration of gadolinium (Gd) based contrast agents are considered important biomarkers and multiple methods have been suggested for quantifying myocardial T1 in vi...